#AACRBlog ▶️ Intersting read re: "Peto’s paradox" 🐘...and the recent #CancerDiscovery story from Compton et al. re: cancer prevalence across vertebrates!
aacrjournals.org/cancerdiscov...
aacrjournals.org/cancerdiscov...
November 20, 2024 at 1:48 AM
#AACRBlog ▶️ Intersting read re: "Peto’s paradox" 🐘...and the recent #CancerDiscovery story from Compton et al. re: cancer prevalence across vertebrates!
aacrjournals.org/cancerdiscov...
aacrjournals.org/cancerdiscov...
A study published in #CancerDiscovery reveals why some colorectal cancers withstand pharmacological inhibition of #KRAS oncogene activity.
Read more here ➡️ https://bit.ly/3L0Cl2G
#CancerResearch olorectalCancer%C2%A0@batllelab.bsky.social%C2%A0" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#ColorectalCancer @batllelab.bsky.social
🧪
Read more here ➡️ https://bit.ly/3L0Cl2G
#CancerResearch olorectalCancer%C2%A0@batllelab.bsky.social%C2%A0" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#ColorectalCancer @batllelab.bsky.social
🧪
October 23, 2025 at 2:03 PM
A study published in #CancerDiscovery reveals why some colorectal cancers withstand pharmacological inhibition of #KRAS oncogene activity.
Read more here ➡️ https://bit.ly/3L0Cl2G
#CancerResearch olorectalCancer%C2%A0@batllelab.bsky.social%C2%A0" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#ColorectalCancer @batllelab.bsky.social
🧪
Read more here ➡️ https://bit.ly/3L0Cl2G
#CancerResearch olorectalCancer%C2%A0@batllelab.bsky.social%C2%A0" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#ColorectalCancer @batllelab.bsky.social
🧪
My main PhD project is out in #CancerDiscovery @theaacr.bsky.social
We found that PKC activators (TPPB) destroy tumor microtube networks that glioblastoma cells use to invade & resist therapy.
Huge thanks to my first co-author @dirkchoffmann.bsky.social , @winklerlab.bsky.social & all co-authors!
We found that PKC activators (TPPB) destroy tumor microtube networks that glioblastoma cells use to invade & resist therapy.
Huge thanks to my first co-author @dirkchoffmann.bsky.social , @winklerlab.bsky.social & all co-authors!
How to disconnect therapy-resistant tumor networks in glioblastoma?
In our paper, online @Cancer Discovery, we built an anti-tumor microtube (TM) screening pipeline and found that Protein Kinase C activators disrupt TMs, silence Ca²⁺ “pacemakers” and boost radiotherapy.
doi.org/10.1158/2159...
In our paper, online @Cancer Discovery, we built an anti-tumor microtube (TM) screening pipeline and found that Protein Kinase C activators disrupt TMs, silence Ca²⁺ “pacemakers” and boost radiotherapy.
doi.org/10.1158/2159...
October 10, 2025 at 7:21 AM
My main PhD project is out in #CancerDiscovery @theaacr.bsky.social
We found that PKC activators (TPPB) destroy tumor microtube networks that glioblastoma cells use to invade & resist therapy.
Huge thanks to my first co-author @dirkchoffmann.bsky.social , @winklerlab.bsky.social & all co-authors!
We found that PKC activators (TPPB) destroy tumor microtube networks that glioblastoma cells use to invade & resist therapy.
Huge thanks to my first co-author @dirkchoffmann.bsky.social , @winklerlab.bsky.social & all co-authors!
➡️ This important video was missing from yesterday’s #Bluetorial.
CRC organoids under treatment with KRAS inhibitor RMC-9945, rapidly acquire a LGR5+ cancer stem cell-like phenotype, allowing them to bypass KRAS inhibition, and eventually resume growth.
Centonze et al., in #CancerDiscovery
#AACR
CRC organoids under treatment with KRAS inhibitor RMC-9945, rapidly acquire a LGR5+ cancer stem cell-like phenotype, allowing them to bypass KRAS inhibition, and eventually resume growth.
Centonze et al., in #CancerDiscovery
#AACR
October 24, 2025 at 6:47 AM
➡️ This important video was missing from yesterday’s #Bluetorial.
CRC organoids under treatment with KRAS inhibitor RMC-9945, rapidly acquire a LGR5+ cancer stem cell-like phenotype, allowing them to bypass KRAS inhibition, and eventually resume growth.
Centonze et al., in #CancerDiscovery
#AACR
CRC organoids under treatment with KRAS inhibitor RMC-9945, rapidly acquire a LGR5+ cancer stem cell-like phenotype, allowing them to bypass KRAS inhibition, and eventually resume growth.
Centonze et al., in #CancerDiscovery
#AACR
June 18, 2025 at 1:43 PM
Honored to have our recently published first-in-human phase 1 clinical trial of repeatedly dosed intracerebroventrocular B7-H3 #CARTcells for children with #DIPG highlighted in @theaacr.bsky.social and #CancerDiscovery Research Watch ❤️🔬
BrainChild-03 Trial Supports Safety of B7-H3 CAR T-cell Therapy for DIPG
Main Finding: A phase I trial supported the safety and feasibility of repeated intracranial infusions of B7-H3 CAR T cells for DIPG.Concept: B7-H3 is an immunoregulatory protein expressed on the surfa...
aacrjournals.org
January 28, 2025 at 6:48 PM
Honored to have our recently published first-in-human phase 1 clinical trial of repeatedly dosed intracerebroventrocular B7-H3 #CARTcells for children with #DIPG highlighted in @theaacr.bsky.social and #CancerDiscovery Research Watch ❤️🔬
Cancer Discovery – Reflections on Advances in Cancer Research in 2024
@alejofraticelli.bsky.social
oncodaily.com/blog/cancer-...
#Cancer #CancerDiscovery #OncoDaily #Oncology #Medicine #Health
@alejofraticelli.bsky.social
oncodaily.com/blog/cancer-...
#Cancer #CancerDiscovery #OncoDaily #Oncology #Medicine #Health
Cancer Discovery - Reflections on Advances in Cancer Research in 2024 - OncoDaily
Cancer Discovery - Reflections on Advances in Cancer Research in 2024 / Aadel Chaudhuri, Alejo E. Rodriguez-Fraticelli, Benjamin Izar, Brittany D. Jenkins,
oncodaily.com
December 18, 2024 at 3:38 PM
Cancer Discovery – Reflections on Advances in Cancer Research in 2024
@alejofraticelli.bsky.social
oncodaily.com/blog/cancer-...
#Cancer #CancerDiscovery #OncoDaily #Oncology #Medicine #Health
@alejofraticelli.bsky.social
oncodaily.com/blog/cancer-...
#Cancer #CancerDiscovery #OncoDaily #Oncology #Medicine #Health
Congratulations @braunmdphd.bsky.social, recipient of the @theaacr.bsky.social Cancer Discovery Early Career Award, which recognizes outstanding early career investigators who have authored peer-reviewed, original articles published in #CancerDiscovery. Dr. Braun will receive his award at #AACR26.
April 17, 2026 at 8:24 PM
Congratulations @braunmdphd.bsky.social, recipient of the @theaacr.bsky.social Cancer Discovery Early Career Award, which recognizes outstanding early career investigators who have authored peer-reviewed, original articles published in #CancerDiscovery. Dr. Braun will receive his award at #AACR26.
📢Announcing a call for commentaries! Cancer Discovery wants to hear YOUR thoughts that challenge existing paradigms/shed new light on emerging topics in cancer. Selected pieces will be published in April 2024 and showcased during #AACR24! Email cancerdiscovery@aacr.org with proposals by Nov. 1.
September 27, 2023 at 2:39 PM
📢Announcing a call for commentaries! Cancer Discovery wants to hear YOUR thoughts that challenge existing paradigms/shed new light on emerging topics in cancer. Selected pieces will be published in April 2024 and showcased during #AACR24! Email cancerdiscovery@aacr.org with proposals by Nov. 1.
Congratulations to our poster prize winners at our Cancer Grand Challenges Conference: Spatial biology! 🎉
Soham Mandal, @icr.ac.uk, won the @natrevcancer.nature.com prize.
Emine Kazanc, @icr.ac.uk, won the @aacrjournals.bsky.social #CancerDiscovery prize.
A huge thank you to both journals.
Soham Mandal, @icr.ac.uk, won the @natrevcancer.nature.com prize.
Emine Kazanc, @icr.ac.uk, won the @aacrjournals.bsky.social #CancerDiscovery prize.
A huge thank you to both journals.
September 4, 2026 at 9:24 AM
Congratulations to our poster prize winners at our Cancer Grand Challenges Conference: Spatial biology! 🎉
Soham Mandal, @icr.ac.uk, won the @natrevcancer.nature.com prize.
Emine Kazanc, @icr.ac.uk, won the @aacrjournals.bsky.social #CancerDiscovery prize.
A huge thank you to both journals.
Soham Mandal, @icr.ac.uk, won the @natrevcancer.nature.com prize.
Emine Kazanc, @icr.ac.uk, won the @aacrjournals.bsky.social #CancerDiscovery prize.
A huge thank you to both journals.
💡Un estudi liderat pels #investigadorICREA Eduard Batlle, @mamartirenom.bsky.social i Carme Cortina del @irbbarcelona.org @cnag-eu.bsky.social revela per què alguns càncers colorectals amb mutació KRAS poden esquivar els medicaments.
☝️No et perdis el fil de @batllelab.bsky.social: short.do/iLl6i4
☝️No et perdis el fil de @batllelab.bsky.social: short.do/iLl6i4
The Batlle Lab (@batllelab.bsky.social)
🧵1/17
📣Thrilled to share our latest study just out in Cancer Discovery!
➡️
https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-25-0679/766696/A-plastic-EMP1-to-LGR5-cell-state...
short.do
November 14, 2025 at 9:58 AM
💡Un estudi liderat pels #investigadorICREA Eduard Batlle, @mamartirenom.bsky.social i Carme Cortina del @irbbarcelona.org @cnag-eu.bsky.social revela per què alguns càncers colorectals amb mutació KRAS poden esquivar els medicaments.
☝️No et perdis el fil de @batllelab.bsky.social: short.do/iLl6i4
☝️No et perdis el fil de @batllelab.bsky.social: short.do/iLl6i4
Grateful to have our work presented at @ash-hematology.bsky.social #ASH24 highlighted by #cancerdiscovery, showcasing the increased risk of pre-leukemic clonal hematopoiesis in 9/11-exposed first responders. @einsteinmededu.bsky.social
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
9/11 First Responders Have Twofold Increase in Leukemia Precursor
Firefighters and emergency medical personnel who worked at Ground Zero after the September 11 attacks are twice as likely to have clonal hematopoiesis (CH)––which, in rare cases, can lead to blood can...
aacrjournals.org
December 17, 2024 at 4:26 AM
Grateful to have our work presented at @ash-hematology.bsky.social #ASH24 highlighted by #cancerdiscovery, showcasing the increased risk of pre-leukemic clonal hematopoiesis in 9/11-exposed first responders. @einsteinmededu.bsky.social
aacrjournals.org/cdnews/news/...
aacrjournals.org/cdnews/news/...
Full study out now in CancerDiscovery: bit.ly/4v2Vjaz
🧵5/5
#PancreaticCancer #CancerResearch #Oncology
🧵5/5
#PancreaticCancer #CancerResearch #Oncology
2026 News
bit.ly
May 22, 2026 at 9:24 PM
Full study out now in CancerDiscovery: bit.ly/4v2Vjaz
🧵5/5
#PancreaticCancer #CancerResearch #Oncology
🧵5/5
#PancreaticCancer #CancerResearch #Oncology
Overall cancer incidence in the U.S. among people under age 50 years was relatively flat, 2010 - 2019, while overall deaths from early-onset cancer declined, @theaacr.bsky.social #CancerDiscovery aacrjournals.org/cancerdiscov...
May 9, 2025 at 12:50 PM
Overall cancer incidence in the U.S. among people under age 50 years was relatively flat, 2010 - 2019, while overall deaths from early-onset cancer declined, @theaacr.bsky.social #CancerDiscovery aacrjournals.org/cancerdiscov...
KF: G9a as a "driver" of melanoma de-differentiation. G9a expression associated with immune exclusion #AACRprecmed25 https://aacrjournals.org/cancerdiscovery/article-abstract/10/7/980/2666/Gain-of-Function-Genetic-Alterations-of-G9a-Drive
March 11, 2025 at 9:43 PM
KF: G9a as a "driver" of melanoma de-differentiation. G9a expression associated with immune exclusion #AACRprecmed25 https://aacrjournals.org/cancerdiscovery/article-abstract/10/7/980/2666/Gain-of-Function-Genetic-Alterations-of-G9a-Drive
New data from the KRYSTAL-1 trial reveals adagrasib + cetuximab demonstrates 34% ORR and 15.9 months mOS in heavily pretreated patients with #KRAS G12C-mutated metastatic #CRC! 💊🔬
@theaacr.bsky.social #cancerdiscovery
#Onco404 #Cancer #Kanser #ColorectalCancer #ClinicalTrials #PrecisionMedicine
@theaacr.bsky.social #cancerdiscovery
#Onco404 #Cancer #Kanser #ColorectalCancer #ClinicalTrials #PrecisionMedicine
May 6, 2025 at 3:32 PM
New data from the KRYSTAL-1 trial reveals adagrasib + cetuximab demonstrates 34% ORR and 15.9 months mOS in heavily pretreated patients with #KRAS G12C-mutated metastatic #CRC! 💊🔬
@theaacr.bsky.social #cancerdiscovery
#Onco404 #Cancer #Kanser #ColorectalCancer #ClinicalTrials #PrecisionMedicine
@theaacr.bsky.social #cancerdiscovery
#Onco404 #Cancer #Kanser #ColorectalCancer #ClinicalTrials #PrecisionMedicine
So excited to share our latest work! An immunomechanical checkpoint PYK2 governs monocyte-to-macrophage differentiation in pancreatic cancer url:https://aacrjournals.org/cancerdiscovery/article-abstract/doi/10.1158/2159-8290.CD-24-1712/762294/An-immunomechanical-checkpoint-PYK2-governs
May 9, 2025 at 12:32 PM
So excited to share our latest work! An immunomechanical checkpoint PYK2 governs monocyte-to-macrophage differentiation in pancreatic cancer url:https://aacrjournals.org/cancerdiscovery/article-abstract/doi/10.1158/2159-8290.CD-24-1712/762294/An-immunomechanical-checkpoint-PYK2-governs
Dr. Samir Zaidi received an @theaacr.bsky.social Trailblazer Cancer Research Grant earlier this year + in the latest #CancerDiscovery @aacrjournals.bsky.social he shares commentary on his research project, Decoding Lineage Plasticity as the Engine of Therapy Escape."
aacrjournals.org/cancerdiscov...
aacrjournals.org/cancerdiscov...
Insights on Future Directions in Cancer Research from the AACR Trailblazer Cancer Research Grant Awardees
The American Association for Cancer Research (AACR) Trailblazer Cancer Research Grant Program is a historic initiative intended to provide talented investigators with the resources to support innovati...
aacrjournals.org
September 4, 2026 at 5:23 PM
Dr. Samir Zaidi received an @theaacr.bsky.social Trailblazer Cancer Research Grant earlier this year + in the latest #CancerDiscovery @aacrjournals.bsky.social he shares commentary on his research project, Decoding Lineage Plasticity as the Engine of Therapy Escape."
aacrjournals.org/cancerdiscov...
aacrjournals.org/cancerdiscov...
#ADCs represent a rapidly expanding frontier in #Oncology! This 40-year journey blends precision targeting 🎯 with potent payloads, yet challenges like toxicity and cross-resistance remind us: balance is key.
#aacr #cancerdiscovery
#Onco404 #Cancer #MedSky #OncSky #Kanser #Biotech #Innovation
#aacr #cancerdiscovery
#Onco404 #Cancer #MedSky #OncSky #Kanser #Biotech #Innovation
April 24, 2025 at 8:59 AM
Every medical student snarks that "I will never need to use the Krebs cycle!"... you will when you try to understand #kidneycancer... and now it seems we also need to understand copper metabolism too. A fascinating paper suggestion #cuproplasia and #cuproptosis might both be in play...
November 18, 2024 at 11:15 AM
Every medical student snarks that "I will never need to use the Krebs cycle!"... you will when you try to understand #kidneycancer... and now it seems we also need to understand copper metabolism too. A fascinating paper suggestion #cuproplasia and #cuproptosis might both be in play...
New research in #CancerDiscovery from @uclaradiology.bsky.social researchers & colleagues shows that intratumoral BO-112 and radiation can turn immune-cold sarcoma's myeloid cells into antigen-presenting allies, drawing in less-exhausted T cells. doi.org/10.1158/2159...
Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results
Intratumoral BO-112 (nanoplexed poly I:C) with hypofractionated radiotherapy engages myeloid cells to promote T cell–mediated immunity across preclinical models and a phase I trial in sarcoma.
doi.org
September 3, 2026 at 7:57 PM
New research in #CancerDiscovery from @uclaradiology.bsky.social researchers & colleagues shows that intratumoral BO-112 and radiation can turn immune-cold sarcoma's myeloid cells into antigen-presenting allies, drawing in less-exhausted T cells. doi.org/10.1158/2159...
🚨 New paper alert. We identified NFIL3 as key regulator of dysfunctional CAR T-cell states. Read the paper in Cancer Discovery: doi.org/10.1158/2159...
We thank our close collaborators at CICET and the iFIT Cluster of Excellence for their support! 🎉
#TeamJJ #CancerDiscovery #CARTcells #iFIT
We thank our close collaborators at CICET and the iFIT Cluster of Excellence for their support! 🎉
#TeamJJ #CancerDiscovery #CARTcells #iFIT
Integrated Chronic In Vivo and In Vitro Screens Uncover NFIL3 as a Driver of T-cell Dysfunction
AbstractChimeric antigen receptor (CAR) therapy has transformed the treatment landscape for hematologic malignancies, but its efficacy in solid tumors is limited, owing in part to insufficient functio...
doi.org
May 15, 2026 at 12:21 PM
🚨 New paper alert. We identified NFIL3 as key regulator of dysfunctional CAR T-cell states. Read the paper in Cancer Discovery: doi.org/10.1158/2159...
We thank our close collaborators at CICET and the iFIT Cluster of Excellence for their support! 🎉
#TeamJJ #CancerDiscovery #CARTcells #iFIT
We thank our close collaborators at CICET and the iFIT Cluster of Excellence for their support! 🎉
#TeamJJ #CancerDiscovery #CARTcells #iFIT
New research reveals how extrachromosomal DNA influences oncogene evolution in glioblastoma, providing deeper insights into tumor biology and potentia...
🔗 Source: https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-24-1555/764257/Extrachromosomal-DNA-Driven-Oncogene-Spatial
🔗 Source: https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-24-1555/764257/Extrachromosomal-DNA-Driven-Oncogene-Spatial
August 23, 2026 at 1:23 AM
New research reveals how extrachromosomal DNA influences oncogene evolution in glioblastoma, providing deeper insights into tumor biology and potentia...
🔗 Source: https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-24-1555/764257/Extrachromosomal-DNA-Driven-Oncogene-Spatial
🔗 Source: https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-24-1555/764257/Extrachromosomal-DNA-Driven-Oncogene-Spatial
➡️ Der Forschungsbericht eines Teams der University of Manchester, 🇬🇧, um Colin Lindsay in der Fachzeitschrift "Cancer Discovery"
https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-25-0884/785967/Targeting-KRAS-codon-13-mutations-using-direct 2/2
https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-25-0884/785967/Targeting-KRAS-codon-13-mutations-using-direct 2/2
July 8, 2026 at 8:44 PM
➡️ Der Forschungsbericht eines Teams der University of Manchester, 🇬🇧, um Colin Lindsay in der Fachzeitschrift "Cancer Discovery"
https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-25-0884/785967/Targeting-KRAS-codon-13-mutations-using-direct 2/2
https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-25-0884/785967/Targeting-KRAS-codon-13-mutations-using-direct 2/2
Activated T Cells Break Tumor Immunosuppression by Macrophage Reeducation url:https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-24-0415/762749/Activated-T-Cells-Break-Tumor-Immunosuppression-by
June 18, 2025 at 1:14 AM
Activated T Cells Break Tumor Immunosuppression by Macrophage Reeducation url:https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-24-0415/762749/Activated-T-Cells-Break-Tumor-Immunosuppression-by